User login
ATLANTA — Transdermal testosterone was no better than placebo for improving libido in female cancer survivors after 4 weeks, according to results of a randomized, blinded, crossover study presented at the annual meeting of the American Society of Clinical Oncology.
In the 131 women who completed the study, testosterone and placebo provided similar significant improvements in libido.
The North Central Cancer Treatment Group's N02C3 study randomized 150 women to receive 10 mg/day transdermal testosterone in Vanicream (Pharmaceutical Specialties, Inc.) or placebo (vehicle alone) for 4 weeks, followed by a crossover to the opposite treatment arm for 4 weeks.
All of the women were postmenopausal with no active disease, and all had reported decreased sexual desire. Those with comorbidities that might confound results were excluded. The women were an average of 52 years old; 31% were receiving aromatase inhibitors during the study, and 47% were receiving tamoxifen. Most (72%) had at least one intact ovary, 80% had received prior chemotherapy, and only 7% had received pelvic radiotherapy.
Efficacy was measured using the Changes in Sexual Functioning Questionnaire (CSFQ) after each 4-week period. The average CSFQ score was 5.5 with testosterone and 4.4 with placebo after the first period and 8.8 and 8.1, respectively, after the second period.
“These results might seem very surprising, given the plethora of evidence that shows that transdermal testosterone is effective,” said study author Debra L. Barton, Ph.D., of the Mayo Clinic College of Medicine, Rochester, Minn., in her presentation. She suggested the exclusion of women on supplemental estradiol in this trial and the relatively short study duration might account for these differences.
ATLANTA — Transdermal testosterone was no better than placebo for improving libido in female cancer survivors after 4 weeks, according to results of a randomized, blinded, crossover study presented at the annual meeting of the American Society of Clinical Oncology.
In the 131 women who completed the study, testosterone and placebo provided similar significant improvements in libido.
The North Central Cancer Treatment Group's N02C3 study randomized 150 women to receive 10 mg/day transdermal testosterone in Vanicream (Pharmaceutical Specialties, Inc.) or placebo (vehicle alone) for 4 weeks, followed by a crossover to the opposite treatment arm for 4 weeks.
All of the women were postmenopausal with no active disease, and all had reported decreased sexual desire. Those with comorbidities that might confound results were excluded. The women were an average of 52 years old; 31% were receiving aromatase inhibitors during the study, and 47% were receiving tamoxifen. Most (72%) had at least one intact ovary, 80% had received prior chemotherapy, and only 7% had received pelvic radiotherapy.
Efficacy was measured using the Changes in Sexual Functioning Questionnaire (CSFQ) after each 4-week period. The average CSFQ score was 5.5 with testosterone and 4.4 with placebo after the first period and 8.8 and 8.1, respectively, after the second period.
“These results might seem very surprising, given the plethora of evidence that shows that transdermal testosterone is effective,” said study author Debra L. Barton, Ph.D., of the Mayo Clinic College of Medicine, Rochester, Minn., in her presentation. She suggested the exclusion of women on supplemental estradiol in this trial and the relatively short study duration might account for these differences.
ATLANTA — Transdermal testosterone was no better than placebo for improving libido in female cancer survivors after 4 weeks, according to results of a randomized, blinded, crossover study presented at the annual meeting of the American Society of Clinical Oncology.
In the 131 women who completed the study, testosterone and placebo provided similar significant improvements in libido.
The North Central Cancer Treatment Group's N02C3 study randomized 150 women to receive 10 mg/day transdermal testosterone in Vanicream (Pharmaceutical Specialties, Inc.) or placebo (vehicle alone) for 4 weeks, followed by a crossover to the opposite treatment arm for 4 weeks.
All of the women were postmenopausal with no active disease, and all had reported decreased sexual desire. Those with comorbidities that might confound results were excluded. The women were an average of 52 years old; 31% were receiving aromatase inhibitors during the study, and 47% were receiving tamoxifen. Most (72%) had at least one intact ovary, 80% had received prior chemotherapy, and only 7% had received pelvic radiotherapy.
Efficacy was measured using the Changes in Sexual Functioning Questionnaire (CSFQ) after each 4-week period. The average CSFQ score was 5.5 with testosterone and 4.4 with placebo after the first period and 8.8 and 8.1, respectively, after the second period.
“These results might seem very surprising, given the plethora of evidence that shows that transdermal testosterone is effective,” said study author Debra L. Barton, Ph.D., of the Mayo Clinic College of Medicine, Rochester, Minn., in her presentation. She suggested the exclusion of women on supplemental estradiol in this trial and the relatively short study duration might account for these differences.